Wednesday, January 29, 2025

Medical Therapeutic Stock Aethlon Medical, Inc. (NASDAQ: $AEMD) Gains on Cancer Clinical Trial update

 

 


Medical Therapeutic Stock Aethlon Medical, Inc. (NASDAQ: $AEMD) Gains on Cancer Clinical Trial update

 



 


Investorideas.com (www.investorideas.com) a go-to platform for big investing ideas for stock traders, including  biotech  and medical tech stocks reports on trading and news for  Aethlon Medical, Inc. (Nasdaq: AEMD), a medical therapeutic company focused on developing products to treat cancer and life-threatening infectious diseases.

 

Aethlon is trading up today, currently at $0.6930, up 0.0700, gaining 11.1643% on over 2.1 Million shares. The stock has a day’s high of $0.75 as of this report.

 

Aethlon Medical, Inc. (Nasdaq: AEMDtoday announced a significant milestone: the treatment of the first patient with the Hemopurifier in its Australian safety, feasibility and dose-finding clinical trial of the Hemopurifier. This trial is designed for patients with solid tumors who have stable or progressive disease during anti-PD-1 monotherapy treatment, such as Keytruda® (pembrolizumab) or Opdivo® (nivolumab) (AEMD-2022-06 Hemopurifier Study). The patient was enrolled on October 29, 2024, by Prof. Michael Brown and his staff at the Cancer Clinical Trials Unit, CALHN, Royal Adelaide Hospital in Australia, and treated with the Hemopurifer on January 29, 2025, by Prof. Toby Coates and the dialysis staff.

 

Paid News Dissemination of behalf of AEMD.

 

Read this news, featuring AEMD in full at https://www.investorideas.com/news/2025/biotech/01291Medical-Therapeutic-Stock-AEMD.asp

 

The patient treated was determined to have progressive disease following a two-month "run -in" period of the anti-PD-1 drug Nivolumab. During this period, serial measurements of extracellular vesicles (EVs) and anti-tumor T cell activity were obtained. The patient was then treated with the Aethlon Hemopurifier for 4 hours on a single day and tolerated the procedure without complications. The patient will have follow-up safety visits, EV and T cell measurements as well as imaging for clinical response.

 

"Treatment of the first patient represents the achievement of a critical milestone for Aethlon Medical in the clinical development of the Hemopurifier in Oncology," stated Steven LaRosa, MD, Chief Medical Officer of Aethlon Medical. "We are excited to receive the data from this first treatment cohort, anticipating insights into how the Hemopurifier may reduce tumor-derived extracellular vesicles and enhance T cell activity against tumors".

 

Currently, only approximately 30-40% of patients who receive pembrolizumab or nivolumab will have lasting clinical responses to these agents. EVs produced by tumors have been implicated in the spread of cancers as well as the resistance to anti-PD-1 therapies. The Aethlon Hemopurifier has been designed to bind and remove these EVs from the bloodstream, which may improve therapeutic response rates to anti-PD-1 antibodies. In preclinical studies, the Hemopurifier has been shown to reduce the number of exosomes from the plasma of cancer patient samples.

 

The primary endpoint of the approximately 18-patient, safety, feasibility, and dose-finding trial is the incidence of adverse events and clinically significant changes in safety lab tests of Hemopurifier treated patients with solid tumors with stable or progressive disease at different treatment intervals, after a two-month run-in period of PD-1 antibody, Keytruda® or Opdivo® monotherapy. Patients who do not respond to the therapy will be eligible to enter the Hemopurifier period of the study where sequential cohorts will receive 1, 2, or 3 Hemopurifier treatments during a one-week period. In addition to monitoring safety, the study is designed to examine the number of Hemopurifier treatments needed to decrease the concentration of EVs and if these changes in EV concentrations improve the body's own natural ability to attack tumor cells. These exploratory central laboratory analyses are expected to inform the design of a subsequent efficacy and safety, Premarket Approval (PMA), study required by regulatory agencies.

 

Recent news release

https://www.investorideas.com/news/2025/01291AEMD-Treats-First-Patient-in-Australian-Hemopurifier-Cancer-Trial.asp

 

Biotech stocks to watch:

Research more Biotech and medical technology stocks with Investorideas.com free stock directory

 

About Investorideas.com - Big Investing Ideas

Investorideas.com is the go-to platform for big investing ideas. From breaking stock news to top-rated investing podcasts, we cover it all. Our original branded content includes podcasts such as Exploring Mining, Cleantech, Crypto Corner, Cannabis News, and the AI Eye. We also create free investor stock directories for sectors including mining, crypto, renewable energy, gaming, biotech, tech, sports and more. Public companies within the sectors we cover can use our news publishing and content creation services to help tell their story to interested investors.

 

Disclaimer/Disclosure: This news alert for AEMD is part of Investorideas.com paid content on behalf of Aethlon Medical. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. All investing involves risk and possible losses. This site is currently compensated for news publication and distribution, social media and marketing, content creation and more.. Contact management and IR of each company directly regarding specific questions. More disclaimer info: https://www.investorideas.com/About/Disclaimer.asp 

Global investors must adhere to regulations of each country. Please read Investorideas.com privacy poilicy: https://www.investorideas.com/About/Private_Policy.asp

Learn more about our news, IR, PR and social media, podcast sponsorship and ticker tag content creation services at Investorideas.com

https://www.investorideas.com/Investors/Services.asp

 

Learn more about digital advertising and guest posts/sponsored posts

https://www.investorideas.com/Advertise/

 

Follow us on X @investorideas @stocknewsbites

Follow us on Facebook https://www.facebook.com/Investorideas

Follow us on YouTube https://www.youtube.com/c/Investorideas

 

Sign up for free stock news alerts at Investorideas.com

 

Contact Investorideas.com

800 665 0411

 



Biotech Industry Stocks- investing ideas in biotechnology stocks, medical technology and life sciences

Get more biotech and medical tech news, articles, podcasts and stock directories

 

Breaking Medical Technology News: Aethlon Medical (NASDAQ: $AEMD) Treats First Patient in Australian Hemopurifier® Cancer Trial

 

Breaking Medical Technology News: Aethlon Medical (NASDAQ: $AEMD) Treats First Patient in Australian Hemopurifier® Cancer Trial

 

First Patient enrolled and treated at the Cancer Clinical Trial Unit, CALHN, Royal Adelaide Hospital

 

Aethlon Advances Hemopurifier® Study in Solid Tumors Not Responding to Anti-PD-1 Antibodies



 

SAN DIEGO, CA- January 29, 2025 (Investorideas.com Newswire) Aethlon Medical, Inc. (Nasdaq: AEMD), a medical therapeutic company focused on developing products to treat cancer and life-threatening infectious diseases, today announced a significant milestone: the treatment of the first patient with the Hemopurifier in its Australian safety, feasibility and dose-finding clinical trial of the Hemopurifier. This trial is designed for patients with solid tumors who have stable or progressive disease during anti-PD-1 monotherapy treatment, such as Keytruda® (pembrolizumab) or Opdivo® (nivolumab) (AEMD-2022-06 Hemopurifier Study). The patient was enrolled on October 29, 2024, by Prof. Michael Brown and his staff at the Cancer Clinical Trials Unit, CALHN, Royal Adelaide Hospital in Australia, and treated with the Hemopurifer on January 29, 2025, by Prof. Toby Coates and the dialysis staff.

 

The patient treated was determined to have progressive disease following a two-month "run -in" period of the anti-PD-1 drug Nivolumab. During this period, serial measurements of extracellular vesicles (EVs) and anti-tumor T cell activity were obtained. The patient was then treated with the Aethlon Hemopurifier for 4 hours on a single day and tolerated the procedure without complications. The patient will have follow-up safety visits, EV and T cell measurements as well as imaging for clinical response.

 

Paid News Dissemination of behalf of AEMD.

 

Read this news featuring AEMD in full at https://www.investorideas.com/news/2025/01291AEMD-Treats-First-Patient-in-Australian-Hemopurifier-Cancer-Trial.asp

 

"Treatment of the first patient represents the achievement of a critical milestone for Aethlon Medical in the clinical development of the Hemopurifier in Oncology," stated Steven LaRosa, MD, Chief Medical Officer of Aethlon Medical. "We are excited to receive the data from this first treatment cohort, anticipating insights into how the Hemopurifier may reduce tumor-derived extracellular vesicles and enhance T cell activity against tumors".

 

Currently, only approximately 30-40% of patients who receive pembrolizumab or nivolumab will have lasting clinical responses to these agents. EVs produced by tumors have been implicated in the spread of cancers as well as the resistance to anti-PD-1 therapies. The Aethlon Hemopurifier has been designed to bind and remove these EVs from the bloodstream, which may improve therapeutic response rates to anti-PD-1 antibodies. In preclinical studies, the Hemopurifier has been shown to reduce the number of exosomes from the plasma of cancer patient samples.

 

The primary endpoint of the approximately 18-patient, safety, feasibility, and dose-finding trial is the incidence of adverse events and clinically significant changes in safety lab tests of Hemopurifier treated patients with solid tumors with stable or progressive disease at different treatment intervals, after a two-month run-in period of PD-1 antibody, Keytruda® or Opdivo® monotherapy. Patients who do not respond to the therapy will be eligible to enter the Hemopurifier period of the study where sequential cohorts will receive 1, 2, or 3 Hemopurifier treatments during a one-week period. In addition to monitoring safety, the study is designed to examine the number of Hemopurifier treatments needed to decrease the concentration of EVs and if these changes in EV concentrations improve the body's own natural ability to attack tumor cells. These exploratory central laboratory analyses are expected to inform the design of a subsequent efficacy and safety, Premarket Approval (PMA), study required by regulatory agencies.

 

About the Hemopurifier®

The Aethlon Hemopurifier is an investigational medical device designed to remove enveloped viruses and tumor-derived extracellular vesicles from circulation. The Hemopurifier is an extracorporeal device that is used in concert with a blood pump. The device incorporates plasma separation, size exclusion, and affinity binding to an affinity resin containing a plant lectin. Mannose on the surface of enveloped viruses and extracellular vesicles binds to the plant lectin within the device. Extracellular vesicles released from solid tumors have been implicated in the spread of cancers known as metastasis as well as in the resistance to immunotherapy and chemotherapeutic agents. Removal of enveloped viruses and extracellular vesicles has been observed in in vitro studies and in human subjects. The Hemopurifier holds a U.S. Food and Drug Breakthrough Device for the treatment of individuals with advanced or metastatic cancer who are either unresponsive to or intolerant of standard-of-care therapy. The Hemopurifier also holds an FDA Breakthrough Device designation and an open Investigational Device Exemption (IDE) application related to the treatment of life-threatening viruses that are not addressed with approved therapies.

 

About Aethlon Medical, Inc.

Aethlon Medical, Inc. is a publicly traded medical device company based in San Diego, California. The company aims to leverage its therapeutic device, The Hemopurifier, to remove enveloped viruses and extracellular vesicles from biologic fluids. Aethlon Medical's innovative platform is enabling the development of new options for cancer and life-threatening infectious diseases. For more information on Aethlon Medical, Inc. and its clinical development program, visit www.AethlonMedical.com and follow the company on LinkedIn.

 

Forward Looking Statements

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 that involve risks and uncertainties. Statements containing words such as "may," "believe," "anticipate," "expect," "intend," "plan," "project," "will," "projections," "estimate," "potentially" or similar expressions constitute forward-looking statements. Such forward-looking statements are subject to significant risks and uncertainties and actual results may differ materially from the results anticipated in the forward-looking statements. These forward-looking statements are based upon Aethlon's current expectations and involve assumptions that may never materialize or may prove to be incorrect. Factors that may contribute to such include, without limitation, the number of patients who receive pembrolizumab or nivolumab that will have lasting clinical responses to these agents; the possibility of novel treatment strategies; how the Hemopurifier may reduce tumor-derived extracellular vesicles and enhance T cell activity against tumors; the efficacy of continued clinical trials. The foregoing list of risks and uncertainties is illustrative but is not exhaustive. Additional factors that could cause results to differ materially from those anticipated in forward-looking statements can be found under the caption "Risk Factors" in the Company's Annual Report on Form 10-K for the year ended March 31, 2023, and in the Company's other filings with the Securities and Exchange Commission, including its quarterly Reports on Form 10-Q. All forward-looking statements contained in this press release speak only as of the date on which they were made. Except as may be required by law, the Company does not intend, nor does it undertake any duty, to update this information to reflect future events or circumstances.

 

Company Contact:
Jim Frakes
Chief Executive Officer and Chief Financial Officer
Aethlon Medical, Inc.
Jfrakes@aethlonmedical.com

 

Investor Contact:
Susan Noonan
S.A. Noonan Communications, LLC
susan@sanoonan.com

 

SOURCE Aethlon Medical, Inc.

 

Aethlon Medical Inc. (Nasdaq:AEMD) is a featured biotech stock on Investorideas.com

 

More info on AEMD at Investorideas.com Visit: 

https://www.investorideas.com/CO/AEMD/

 

Get News Alerts on Aethlon Medical

 

Disclaimer/Disclosure: Investorideas.com is a digital publisher of third party sourced news, articles and equity research as well as creates original content, including video, interviews and articles. Original content created by investorideas is protected by copyright laws other than syndication rights. Our site does not make recommendations for purchases or sale of stocks, services or products. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. All investing involves risk and possible losses. This site is currently compensated for news publication and distribution, social media and marketing, content creation and more. Disclosure is posted for each compensated news release, content published /created if required but otherwise the news was not compensated for and was published for the sole interest of our readers and followers. Contact management and IR of each company directly regarding specific questions. Disclosure: Aethlon Medical, Inc. (NASDAQ:AEMD) is a paid featured stock on Investorideas.com More disclaimer info:  https://www.investorideas.com/About/News/Clientspecifics.asp  https://www.investorideas.com/About/Disclaimer.asp

Learn more about publishing your news release and our other news services on the Investorideas.com newswire https://www.investorideas.com/News-Upload/ Global investors must adhere to regulations of each country. Please read Investorideas.com privacy policy: https://www.investorideas.com/About/Private_Policy.asp

 

 



Biotech Industry Stocks- investing ideas in biotechnology stocks, medical technology and life sciences

Get more biotech and medical tech news, articles, podcasts and stock directories

 

Tuesday, January 28, 2025

Exploring Mining Shares VRIC 2025 Top Picks; Stocks Mentioned (TSXV: $LIFT.V; OTCQX: $LIFFF), (TSXV: $TECT.V; OTCQB: $TETOF) (TSXV: $AGAG.V)



 

Exploring Mining Shares VRIC 2025 Top Picks; Stocks Mentioned (TSXV: $LIFT.V; OTCQX: $LIFFF), (TSXV: $TECT.V; OTCQB: $TETOF) (TSXV: $AGAG.V)

 

January 28, 2025 Investorideas.com, a global investor news source covering mining and metals stocks releases a special edition of the  Exploring Mining Podcast . Host Cali Van Zant attended the recent Vancouver Resource Investment Conference, January 19th and 20th and interviewed management of mining companies live on site.

 

Cali shares exclusive insights from the VRIC 2025 conference and interviews with her favorite companies.

 

Join host Cali Van Zant as she talks to industry leaders from Li-FT Power Ltd., Tectonic Metals Inc., and Argenta Silver Corp., uncovering their groundbreaking projects and strategies for creating shareholder value.  Whether you're an experienced investor or new to the mining sector, these special edition videos are packed with valuable information

 

First round of companies includes Li-FT Power Ltd. (TSX-V: LIFT) (OTCQX: LIFFF), Tectonic Metals Inc. (TSX-V: TECT; OTCQB: TETOF) and Argenta Silver Corp. (TSX-V: AGAG)

 

Read this in full at https://www.investorideas.com/news/2025/exploring-mining/01281VRIC-2025-Top-Picks.asp

 

Watch on YouTube:



Top picks from VRIC 2025; Li-FT Power (TSXV: LIFT)

https://youtu.be/XWVNETlxC0M

Interview with Francis Macdonald, CEO & Director of Li-FT Power Ltd. (TSXV: LIFT) (OTCQX: LIFFF):

LIFT is a mineral exploration company engaged in the acquisition, exploration, and development of lithium pegmatite projects located in Canada. The Company’s flagship project is the Yellowknife Lithium Project located in Northwest Territories, Canada. LIFT also holds three early-stage exploration properties in Quebec, Canada with excellent potential for the discovery of buried lithium pegmatites, as well as the Cali Project in Northwest Territories within the Little Nahanni Pegmatite Group. More info at https://www.li-ft.com/

 



Top picks from VRIC 2025; Tectonic Metals Inc. (TSXV: TECT)

https://youtu.be/46lVuBrPJVk

Interview with Tony Reda, President and Chief Executive Officer of Tectonic Metals Inc. (TSX-V: TECT; OTCQB: TETOF):

Tectonic Metals Inc. is a mineral exploration company created and operated by an experienced and well-respected technical and financial team with a track record of wealth creation for shareholders. Key members of the Tectonic team were involved with Kaminak Gold Corporation, the Company that raised C$165 million to fund the acquisition, discovery and advancement of the Coffee Gold Project in the Yukon Territory through to the completion of a bankable feasibility study before selling the multi-million-ounce gold project to Goldcorp Inc. (now Newmont Goldcorp) for C$520 million in 2016. Tectonic is focused on the acquisition, exploration, discovery and development of mineral resources from district-scale projects in politically stable jurisdictions that have the potential to host world-class orebodies. Whether at home or at work, the Tectonic team is grounded on the following core values: passion, integrity, patience, focus, perseverance, honesty, fairness, accountability, respect and a play big mindset. The Company works for its shareholders and is committed to creating value for them. more info at https://www.tectonicmetals.com/

 


Top Picks from VRIC 2025- Argenta Silver Corp. (TSXV: AGAG)

https://youtu.be/gQ2HzoJShzE

 Interview with Joaquin Marias, Vice President of Exploration and Development at Argenta Silver Corp. (TSXV: AGAG):

Argenta Silver Corp. is a focused silver exploration company committed to advancing projects that support the global energy transition. Our mission is to create sustainable, long-term value for shareholders by acquiring and developing high-potential silver assets in mining-friendly jurisdictions across Latin America. Led by an experienced management team with deep expertise in exploration, finance, and project development, Argenta takes a disciplined, strategic approach to growth. With a strong emphasis on responsible mining practices, we are well-positioned to meet the rising demand for silver—a critical metal in renewable energy and emerging technologies—while building a lasting and successful company. learn more at https://argentasilver.com/

 

The Investorideas.com podcasts are also available on Apple Podcasts, Audible, Spotify, Tunein, Stitcher, Spreaker.com, iHeartRadio, Google Podcasts and most audio platforms available.

 

Visit the Podcast page at Investorideas.com:

https://www.investorideas.com/Audio/

 

Research mining stocks at Investorideas.com with our free mining stocks directory at Investorideas.com https://www.investorideas.com/Gold_Stocks/Stocks_List.asp 

 

About Investorideas.com - Big Investing Ideas

Investorideas.com is the go-to platform for big investing ideas. From breaking stock news to top-rated investing podcasts, we cover it all. Our original branded content includes podcasts such as Exploring Mining, Cleantech, Crypto Corner, Cannabis News, and the AI Eye. We also create free investor stock directories for sectors including mining, crypto, renewable energy, gaming, biotech, tech, sports and more. Public companies within the sectors we cover can use our news publishing and content creation services to help tell their story to interested investors. Paid content is always disclosed.

 

Disclaimer/Disclosure: Investorideas.com is a digital publisher of third party sourced news, articles and equity research as well as creates original content, including video, interviews and articles. Original content created by investorideas is protected by copyright laws other than syndication rights. Our site does not make recommendations for purchases or sale of stocks, services or products. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. All investing involves risk and possible losses.  This is not investment opinion. This site is currently compensated for news publication and distribution, social media and marketing, content creation and more. Disclosure is posted for each compensated news release, content published /created if required but otherwise the news was not compensated for and was published for the sole interest of our readers and followers. Contact management and IR of each company directly regarding specific questions. More disclaimer info: https://www.investorideas.com/About/Disclaimer.asp Learn more about publishing your news release and our other news services on the Investorideas.com newswire https://www.investorideas.com/News-Upload/ and tickertagstocknews.com

Global investors must adhere to regulations of each country. Please read Investorideas.com privacy policy: https://www.investorideas.com/About/Private_Policy.asp

 

Follow us on X @investorideas @Exploringmining

Follow us on Facebook https://www.facebook.com/Investorideas

Follow us on YouTube https://www.youtube.com/c/Investorideas

 

Contact Investorideas.com to be a guest or sponsor this podcast

800-665-0411

 

 


Get more mining stock investor ideas- news, articles, podcasts and stock directories

 


Monday, January 27, 2025

Manufacturing in EV’s and Batteries on the Rise to Meet Global Growth Demands; Stocks Mentioned- (TSXV: $NBM.V; (OTC: $NBMFF) @neo_battery , (NASDAQ: $TSLA), (NASDAQ: $RIVN), (NASDAQ: $LCID), (NASDAQ: $SLDP)

Manufacturing in EV’s and Batteries on the Rise to Meet Global Growth Demands; Stocks Mentioned- (TSXV: $NBM.V; (OTC: $NBMFF) @neo_battery , (NASDAQ: $TSLA), (NASDAQ: $RIVN), (NASDAQ: $LCID), (NASDAQ: $SLDP)

 



 


January 27, 2025 -  Investorideas.com, a global investor news source covering EV and battery stocks releases a snapshot looking at the recent news and milestones in the EV and battery markets featuring NEO Battery Materials Ltd(TSXV: NBM) (OTC: NBMFF), a low-cost silicon anode materials developer that enables longer-running, rapid-charging lithium-ion batteries.  NEO just made headline news announcing Canada’s First Silicon Anode Facility.

 

Stocks mentioned in this article include : Tesla (NASDAQ: TSLA), Rivian Automotive, Inc. (NASDAQ: RIVN), Lucid Group, Inc. (NASDAQ: LCID), Solid Power, Inc. (NASDAQ: SLDP).

 

According to Grandview Research, “The global silicon anode battery market size was estimated at USD 279.29 million in 2023 and is expected to grow at a CAGR of 47.1% from 2024 to 2030. The market is experiencing significant growth, driven by the increasing demand for high-energy density batteries across industries such as consumer electronics, automotive, and renewable energy is a primary driver, as silicon anode batteries provide superior energy storage capabilities compared to traditional lithium-ion batteries.”

 

NEO Battery Materials Ltd(TSXV: NBM) (OTC: NBMFFjust announced it entered into a definitive lease agreement on December 20, 2024, with the City of Windsor, Ontario, securing 8 acres of surplus lands at Windsor Airport. This significant milestone marks a critical step toward establishing Canada’s first advanced silicon anode manufacturing facility, further solidifying NEO’s role in strengthening the Canadian battery value chain.

 

Disclosure: This is a paid for sponsored content featuring NEO Battery Materials Ltd.

 

Read this article, featuring NBM in full at https://www.investorideas.com/news/2025/renewable-energy/01271EV-Batteries-Global-Growth-Demands.asp

 

From the news: Located in one of Canada’s key automotive and battery hubs, NEO will lease 8 acres or 350,000 square feet to construct a commercial plant capable of producing 5,000 tons of silicon anodes annually. Initially planning to invest CAD 69 million, NEO expects to invest approximately CAD 120 million in total over the next 8 years for future expansion of the Windsor facility and value-added projects. The investment is expected to create over 100 skilled jobs when fully operational. NEO’s facility is expected to play a pivotal role in reducing reliance on imported materials and enhancing the resilience of the burgeoning battery supply chain in Ontario and across North America.

 

Continued: With an initial term of 49 years, the Agreement includes tax incentives and favourable lease terms compared to market rates, reflecting Windsor’s commitment to fostering economic growth and innovation in battery technology. Through a Community Improvement Plan, Windsor City Council has approved, in principle, a grant for NEO Battery Materials to support their establishment and operations. NEO’s decision to establish its first North American manufacturing facility in Windsor underscores the Company’s confidence in the region’s infrastructure, workforce, and business-friendly environment.

 

Mr. Drew Dilkens, Mayor of the City of Windsor and Board Chair of Invest WindsorEssex, commented, “Today’s announcement is a testament to Windsor’s strategic location, skilled workforce, and leadership in the automotive and EV industries. NEO Battery Materials’ decision to invest in our city highlights our ability to attract forward-thinking companies that drive innovation and create opportunities for our community. As the Automotive and Automobility Capital of Canada, and one of the most important communities to watch in the province and country, we are excited to welcome NEO to Windsor and look forward to the positive impacts, including job creation, this investment will bring to our region.”

 

Mr. Joe Goncalves, Vice President of Investment Attraction & Strategic Initiatives at Invest WindsorEssex, expressed, “We are thrilled to welcome NEO Battery Materials to Windsor-Essex, a testament to our region’s strategic location and prominence as a global leader in next-generation vehicle production and battery manufacturing. We are proud to support NEO Battery Materials in establishing their innovative operations here and look forward to their continued growth and impact in our community.”

 

“The execution of the Agreement represents a transformative milestone for NEO Battery Materials and the Canadian and Ontario battery ecosystem,” stated Mr. Spencer Huh, Director, President and CEO of NEO. “We are proud to be establishing Canada’s first advanced silicon anode manufacturing facility, enabling us to address the increasing demand for high-performance and cost-effective battery technologies. With a significant investment in the Windsor community, NEO will further bolster Ontario’s clean tech sector and strengthen Canada’s growing leadership in the battery supply chain.”

 

Mr. Tom Schnekenburger, Director of Research Partnerships at the University of Windsor, commented, “Creating a thriving innovation ecosystem in Windsor-Essex comes from collaborations with teams like NEO Battery Materials. These projects are crucial to developing a world-class talent pool and critical to advancing R&D and material discovery.”

 

About City of Windsor

Windsor is the proud International Gateway between Canada and the United States of America, and the largest border city in the country. The city boasts one of the busiest commercial Canada-U.S. border crossings, handling about a third of all Canada-U.S. trade per day. Strategically located, the city has easy access to the Right Honourable Herb Gray Parkway, Highway 401, Highway 3, the Ambassador Bridge, the Windsor-Detroit Tunnel, the Windsor International Airport, and the Detroit Metropolitan Airport. At the municipal level, the City of Windsor is led by a Mayor and City Council who remain committed to making strategic investments in infrastructure, assets, amenities and experiences to support and sustain record growth, while keeping affordability and quality of life top of mind.

 

About Invest WindsorEssex

Invest WindsorEssex is the lead economic development agency for the Windsor-Essex region. The focus of the organization is to develop and execute strategies to retain, expand, attract and help new businesses start-up in Windsor-Essex. Invest WindsorEssex is led by a board of distinguished community leaders. A team of professional staff will assist you with all your location and investment decisions by working one-on-one with businesses, to facilitate the process of starting, growing or locating in Windsor-Essex. investwindsoressex.com

 

About University of Windsor

With a rich history dating back to 1857, the University of Windsor is a comprehensive, student-focused institution with more than 17,000 students enrolled in a broad range of undergraduate and graduate programs in the faculties of Arts, Humanities and Social Sciences, Education, Engineering, Graduate Studies, Human Kinetics, Law, Nursing, Odette School of Business and Science. UWindsor’s mission is to empower positive change through regionally and globally engaged inquiry, learning, scholarship, creative activity and advance bold and impactful research. Visit www.uwindsor.ca to learn more.

 

Grandview Research also noted, “The automotive industry's shift towards electric vehicles further amplifies opportunities, as silicon anode batteries offer superior performance. Moreover, advancements in battery technology and materials are paving the way for innovative applications in consumer electronics and healthcare devices, fueling market growth.”

MarketsandMarkets reports “The global electric vehicle (EV) market is projected to grow from USD 396.4 billion in 2024 to USD 620.3 billion by 2030 at a CAGR of 7.7%.”

 

In early January, Tesla (NASDAQ: TSLA) reported, “In the fourth quarter, we produced approximately 459,000 vehicles, delivered over 495,000 vehicles and deployed 11.0 GWh of energy storage products – a record for both deliveries and deployments.”

 

Tesla will post its financial results for the fourth quarter of 2024 after market close on Wednesday, January 29, 2025.

 

Autonews.com recently reported that Tesla “just launched a freshened version of its wildly popular Model Y crossover in the U.S., starting with a pricey special edition that stickers for $61,380 with shipping, a $12,000 premium over the comparable older version still on sale.”

 

EV stocks saw a short-term pull-back following President Trump eliminating the Biden administration's EV mandate, but Rivian and Lucid are rising again as the market looks at the long-term growth story.

 

Rivian Automotive, Inc. (NASDAQ: RIVN), on January 16th announced it closed its loan agreement with the US Department of Energy’s (DOE) Loan Programs Office (LPO) for up to $6.6 billion (including $6 billion of principal and approximately $600 million of capitalized interest) in financial support for the construction of its next manufacturing facility in Stanton Springs North, near the City of Social Circle, Georgia. These funds will help secure American leadership in electric vehicles while supporting the creation of 7,500 new manufacturing jobs and accelerating the volume expansion of the company’s new R2 SUV and R3 crossover.

 

From the news: Construction is expected to begin in 2026 with the production of customer vehicles expected to take place in 2028. Rivian and the Department of Energy have worked together closely for over two years in order for the loan to proceed to closing.

 

Continued: "This loan will help us accelerate the launch of our Georgia plant for R2 and R3, providing thousands of jobs in the state," said Rivian Founder and CEO RJ Scaringe. "People are incredibly excited to get behind the wheel of our new models, and this additional capacity for our mass market products is key to U.S. leadership in the electric vehicle industry."

 

ON January 6th, Panasonic Energy Co., Ltd., a global leader in the battery industry, and Lucid Group, Inc. (NASDAQ: LCID), maker of the world's most advanced electric vehicles, announced the highly anticipated Lucid Gravity Grand Touring will be powered by Panasonic Energy's lithium-ion EV battery cells. With an EPA-estimated range of up to 450 miles1 from a battery pack that is up to 40 percent smaller than competitors', the collaborative efforts between Panasonic and Lucid have helped deliver an SUV with a previously impossible combination of outstanding range, performance and interior space.

 

From the news: Lucid Gravity is a groundbreaking new class of SUV, conceived from the ground up without compromise. Enabled by Lucid's revolutionary technology, Lucid Gravity provides the interior space and practicality of a full-size SUV with up to 120 cubic feet of total usable cargo space2, all contained inside the exterior footprint of a mid-size SUV. As a result, it provides a sophisticated space for up to seven adults, game-changing versatility, and an unparalleled driving experience. The Lucid Gravity Grand Touring offers 828 horsepower, is capable of 0-60 in under 3.5 seconds, and has an EPA-rated range of up to 450 miles.

 

Another major player in the battery market for EV’s, Solid Power, Inc. (NASDAQ: SLDP), is an industry-leading developer of all-solid-state rechargeable battery technology, primarily for the electric vehicle market. Solid Power replaces the flammable liquid electrolyte contained within a conventional lithium-ion battery with a proprietary sulfide solid electrolyte. As a result, Solid Power's all-solid-state batteries are designed to be safer, more stable at high temperatures, offer higher energy and provide a lower cost alternative to today’s best available lithium-ion batteries, all while being produced with traditional lithium-ion manufacturing processes.

 

The global electric vehicle (EV) battery market size was valued at USD 59.06 billion in 2023 and is projected to grow from USD 67.78 billion in 2024 to USD 111.20 billion by 2032, exhibiting a CAGR of 6.4% during the forecast period.

 

The opportunity is still very much on a growth curve for investors following the sector.   

 

Investors can research more battery and mining stocks at Investorideas.com https://www.investorideas.com/Gold_Stocks/Stocks_List.asp 

 

Research EV stocks at Investorideas.com

https://www.investorideas.com/Companies/RenewableEnergy/Stock_List.asp#EV

 

About Investorideas.com

Investorideas.com is the go-to platform for big investing ideas. From breaking stock news to top-rated investing podcasts, we cover it all. Our original branded content includes podcasts such as Exploring Mining, Cleantech, Crypto Corner, Cannabis News, and the AI Eye. We also create free investor stock directories for sectors including mining, crypto, renewable energy, gaming, biotech, tech, sports and more.

 

Disclaimer/Disclosure: This article featuring NEO Battery Materials Ltd.is a paid for service on Investorideas.com, as a featured cleantech stock.  Our site does not make recommendations for purchases or sale of stocks, services or products. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. All investing involves risk and possible losses. This site is currently compensated for news publication and distribution, social media and marketing, content creation and more. More disclaimer info: https://www.investorideas.com/About/Disclaimer.asp Learn more about publishing your news release and our other news services on the Investorideas.com newswire https://www.investorideas.com/News-Upload/

Global investors must adhere to regulations of each country. Investorideas.com privacy policy: https://www.investorideas.com/About/Private_Policy.asp

 

Follow us on X @investorideas @Exploringmining

Follow us on Facebook https://www.facebook.com/Investorideas

Follow us on YouTube https://www.youtube.com/c/Investorideas

 

Contact Investorideas.com

800-665-0411

 



Renewable Energy Stocks: investing ideas in renewable energy stocks

Like Renewable Energy Stocks? View our Renewable Energy Stocks Directory

Get News Alerts on Renewable Energy Stocks